-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $11

Benzinga·03/28/2025 12:35:14
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $15 to $11.